Prasugrel - Revision history

Elcatracho: /* See Also */

2021-03-06T02:49:11Z

Mholtz: Text replacement - "w/ " to "with "

2017-07-24T01:12:51Z

Text replacement - "w/ " to "with "

← Revisión anterior		Revisión del 01:12 24 jul 2017
Línea 8:		Línea 8:
	10 mg PO QD		10 mg PO QD
	*Start: 60 mg PO x1		*Start: 60 mg PO x1
	**For patients undergoing PCI, give w/ aspirin 75-325 mg PO QD		**For patients undergoing PCI, give with aspirin 75-325 mg PO QD
	**Consider decrease to 5 mg PO QD if < 60 kg		**Consider decrease to 5 mg PO QD if < 60 kg

Mholtz: Text replacement - "qd" to "QD"

2017-07-07T12:12:18Z

Text replacement - "qd" to "QD"

← Revisión anterior		Revisión del 12:12 7 jul 2017
Línea 6:		Línea 6:

	==Adult Dosing==		==Adult Dosing==
	10 mg PO qd		10 mg PO QD
	*Start: 60 mg PO x1		*Start: 60 mg PO x1
	**For patients undergoing PCI, give w/ aspirin 75-325 mg PO qd		**For patients undergoing PCI, give w/ aspirin 75-325 mg PO QD
	**Consider decrease to 5 mg PO qd if < 60 kg		**Consider decrease to 5 mg PO QD if < 60 kg

	==Pediatric Dosing==		==Pediatric Dosing==

Jonwarren: Creation of page

2016-11-12T00:38:20Z

Creation of page

Página nueva

==Administration==
*Type: [[Antiplatelet]]
*Dosage Forms: 5, 10 mg
*Routes of Administration: Oral
*Common Trade Names: Effient

==Adult Dosing==
10 mg PO qd
*Start: 60 mg PO x1
**For patients undergoing PCI, give w/ aspirin 75-325 mg PO qd
**Consider decrease to 5 mg PO qd if < 60 kg

==Pediatric Dosing==
N/A

==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B; No known risk of fetal harm based on animal data at up to 30x MRHD
*[[Lactation risk categories|Lactation risk]]: L3; Safety unknown
===Renal Dosing===
*Adult: No adjustment
*Pediatric: N/A
===Hepatic Dosing===
*Adult: No adjustment for mild impairment. Not defined for severe impairment.
*Pediatric: N/A

==Contraindications==
*Allergy to class/drug
*Hypersensitivity to drug/class/compon.
*Active bleeding
*[[Stroke]] or [[TIA]]
*CABG within 7 days

==Adverse Reactions==
===Serious===
*Severe bleeding
*Hemorrhage
*[[TTP]]
*[[Thrombocytopenia]]
*[[Anemia]]
*[[Leukopenia]]
*Hepatic impairment
*[[Atrial fibrillation]]

===Common===
*Bleeding
*[[Hypertension]]
*Hyperlipidemia
*[[Headache]]
*[[Back pain]]
*[[Dyspnea]]
*[[Nausea]]
*[[Dizziness]]
*[[Cough]]
*[[Hypotension]]
*[[Fatigue]]
*[[Chest pain]]
*[[Atrial fibrillation]]
*[[Bradycardia]]
*[[Leukopenia]]
*[[Rash]]
*[[Fever]]
*Peripheral edema
*Extremity pain
*[[Diarrhea]]

==Pharmacology==
*Half-life: 7 hr
*Metabolism: Liver; CYP450: 2B6, 2C9/19 (minor), 3A4 substrate
*Excretion: Urine 68%, feces 27%

==Mechanism of Action==
Irreversibly binds to P2Y12 adenosine diphosphate receptors, reducing platelet activation and aggregation.

==Comments==

==See Also==

==References==
<references/>
[[Category:Pharmacology]]

← Revisión anterior		Revisión del 02:49 6 mar 2021
Línea 75:		Línea 75:

	==See Also==		==See Also==
			*[[Antiplatelet medications]]
			*[[Antiplatelet agent reversal]]

	==References==		==References==
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]